Ono Pharma and Ionis Enter into License Agreement for Sapablursen to Treat Polycythemia Vera
Shots:
- Ionis has granted Ono Pharma an exclusive global license to develop & commercialize sapablursen for the treatment of polycythemia vera (PV)
- As per the deal, Ionis will get $280M upfront & ~$660M in development, regulatory & sales milestones, plus mid-teens net sales-based royalties as well as Ionis will be responsible to complete ongoing P-II (IMPRSSION) study, while Ono handles further development, regulatory filings & marketing
- Sapablursen reduces TMPRSS6 production, which increases hepcidin levels responsible for iron homeostasis to provide therapeutic relief in blood diseases like PV
Ref: Businesswire | Image: Ono Pharma & Ionis
Related News:- Ono Pharmaceutical Reports the US FDA Approval of Romvimza to Treat Symptomatic Tenosynovial Giant Cell Tumor (TGCT) in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
